[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444575":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":27,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":27,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":27,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":27,"overallStatus":41,"whyStopped":27,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"18F-MFBG PET\u002FCT in neuroendocrine malignancies","EXPERIMENTAL","Each patient receive a single intravenous injection of 18F-MFBG 2-4 MBq\u002Fkg and undergo PET\u002FCT scan after 60 min post-injection. Patients with neuroblastoma should have a routine clinical 123I-MIBG scintigraphy (planar and\u002For SPECT\u002FCT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit. According to patients' condition and clinical management, part of patients with PPGL and NB will receive 68Ga-DOTATATE PET\u002FCT, comparing with 18F-MFBG PET\u002FCT.",[13,14],"Drug: 18F-MFBG","Drug: 68Ga-Dotatate",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","18F-MFBG","Patients with neuroendocrine malignancies receive 2-4 MBq\u002Fkg of 18F-MFBG intravenously followed by PET\u002FCT after 60min of injection.",[9],[22],"18F-metafluorobenzylguanidine",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"68Ga-Dotatate","Patients with malignant PPGL and NB receive intravenously 68Ga-Dotatate followed by PET\u002FCT after 40min of injection.",[9],null,[29],{"name":30,"affiliation":5,"role":31},"Fang Li","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":27,"email":37},"Peipei Wang","CONTACT","18511395988","wpp199411@163.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Peking union medical college hospital","RECRUITING","Beijing","Dongcheng","100010","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":34,"role":35,"phone":36,"phoneExt":27,"email":37},{"type":56,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100444575","early-phase-1-18f-mfbg-petct-in-the-evaluation-of-neural-crest-tumor-100444575",false,"NCT05069220","18F-MFBG PET\u002FCT in the Evaluation of Neural Crest Tumor","A Study of 18F-MFBG Imaging for the Tumor Burden Evaluation or Diagnostic Performance in Pheochromocytoma, Paraganglioma and Neuroblastoma.","Inclusion Criteria:\n\n\\- The subject has read, signed, and dated an informed consent form (ICF) prior to any study procedures being performed. Patients with histologically confirmed or clinically suspicious neural crest tumor.\n\nFor patients with neuroblastoma, subject should have a routine clinical 123I-MIBG scintigraphy (planar + SPECT\u002FCT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit.\n\nThe subject is male or is a nonpregnant, nonlactating female who is either surgically sterile or is post-menopausal. The subject is able and willing to comply with all study procedures as described in the protocol.\n\nExclusion Criteria:\n\n\\- Patients are potentially pregnant (serum and urinary hCG test will be performed in women where pregnancy is not excluded) or is breast-feeding.\n\nPatients undergo surgery between the selection and inclusion visit. Patients who are pregnant, may possibly be pregnant, or wish (including their partners) to become pregnant during the study period, or are lactating. Patients who are not suitable to participate in the trial according to researchers.","ALL","1 Year","80 Years",{"count":68,"type":69},150,"ESTIMATED","INTERVENTIONAL",[72],"EARLY_PHASE1","The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).",[75,76,77,78],"Neuroendocrine Tumor","Neuroblastoma","Pheochromocytoma","Paraganglioma","2024-02-28",{"date":81,"type":82},"2024-03-01","ACTUAL",{"date":84,"type":82},"2021-09-01",{"date":86,"type":69},"2026-12",{"name":5,"class":6},1]